Asset Details
Do you wish to reserve the book?
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
Do you wish to request the book?
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
2018
Overview
Tuberculosis kills more people than any other infectious disease. Three pivotal trials testing 4-month regimens failed to meet non-inferiority margins; however, approximately four-fifths of participants were cured. Through a pooled analysis of patient-level data with external validation, we identify populations eligible for 4-month treatment, define phenotypes that are hard to treat and evaluate the impact of adherence and dosing strategy on outcomes. In 3,405 participants included in analyses, baseline smear grade of 3+ relative to <2+, HIV seropositivity and adherence of ≤90% were significant risk factors for unfavorable outcome. Four-month regimens were non-inferior in participants with minimal disease defined by <2+ sputum smear grade or non-cavitary disease. A hard-to-treat phenotype, defined by high smear grades and cavitation, may require durations >6 months to cure all. Regimen duration can be selected in order to improve outcomes, providing a stratified medicine approach as an alternative to the ‘one-size-fits-all’ treatment currently used worldwide.
Analysis of tuberculosis drug trials identifies features to stratify patients for longer or shorter treatment duration than the standard of care, in order to improve therapeutic outcomes.
Publisher
Nature Publishing Group US,Nature Publishing Group
Subject
/ Analysis
/ Antitubercular Agents - administration & dosage
/ Antitubercular Agents - adverse effects
/ Biomedical and Life Sciences
/ Dose-Response Relationship, Drug
/ Drug administration and dosage
/ Female
/ HIV
/ Human immunodeficiency virus
/ Humans
/ Male
/ Patients
/ Smear
/ Sputum
/ Tuberculosis, Multidrug-Resistant - drug therapy
/ Tuberculosis, Multidrug-Resistant - epidemiology
/ Tuberculosis, Multidrug-Resistant - microbiology
/ Tuberculosis, Multidrug-Resistant - pathology
/ Tuberculosis, Pulmonary - drug therapy
/ Tuberculosis, Pulmonary - epidemiology
